At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Oxfendazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers
In Brief
A Phase 1 clinical trial evaluating Oxfendazole and Placebo for Filariasis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The study evaluates the pharmacokinetics (PK), safety and tolerability of oxfendazole, after administration as a tablet formulation in healthy male and female participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFilariasis
CountriesTanzania
CollaboratorsIfakara Health Institute, Drugs for Neglected Diseases
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartApr 2022
Primary CompletionNov 2022
Study CompletionNov 2022
TodayJul 2026
First PostedJun 9, 2021
Enrollment StartApr 21, 2022
Primary CompletionNov 7, 2022
Study CompletionNov 14, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.1 years ago
Interventions
Oxfendazoledrug
Oxfendazole is a benzimidazole anthelminthic drug.
Placebodrug
The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.